AMD

Duravyu gained 2.5 letters vs 6.1 with aflibercept at week 52/56, missing noninferiority in a second phase 3 wet AMD trial.

AVT29, filed as a line extension to Mynzepli, reaches EMA before its phase 3 comparative trial in DME reads out in mid-2027.

The evidence for nutrition in eye care is strong for some conditions and thin or absent for others.

At the American Academy of Ophthalmology (AAO) 2026 Retina Subspecialty Day in New Orleans, Charles C. Wykoff, MD, PhD, presented 1-year primary end point results from the phase 3 DAYBREAK trial.

Real-world VOYAGER data at EURETINA 2026 show vision and anatomic outcomes with faricimab across nAMD, DME, and RVO.

Three EURETINA 2026 e-posters examine OCT/OCTA biomarkers and real-world switching to faricimab or aflibercept 8 mg in nAMD.

Tarcocimab, tabirafusp-ted were noninferior to aflibercept in DAYBREAK wet AMD trial; 54% on tarcocimab reached 24-week dosing.

Non-invasive electrical stimulation delivered through closed eyelids improved retinal structure and photoreceptor function.

Subretinal deposits are linked to worse surgical risks in patients with severe aortic stenosis and reduced systemic blood flow.

One subretinal injection of medium-dose OCU410 gene therapy reduced geographic atrophy growth by up to 32%.

Q3 2026 delivered advances in some closely watched pipeline products.

Ocugen's global phase 3 ArMaDa3 trial evaluates OCU410, a one-time gene therapy targeting multiple disease pathways in geographic atrophy secondary to dry age-related macular degeneration.

A preclinical study of the effects of aflibercept (Eylea, Regeneron Pharmaceuticals) and faricimab (Vabysmo-svoa, Genentech) showed that the two treatments were equal in their ability to maintain or restore the retinal endothelial barrier function and resultant visual integrity. Investigators attributed this result mainly to inhibiting vascular endothelial growth factor A165 from binding to its receptor.

Topical chloroprocaine hydrochloride ophthalmic gel 3% (IHEEZO, Harrow) resulted in less pain f following intravitreal injections in patients undergoing same-day bilateral intravitreal injections.

Gene therapies, Tie2 agonism, and new delivery platforms are advancing through phase 3 trials in wet and dry AMD, testing mechanisms distinct from anti-VEGF and complement inhibition.

Wet AMD gains a new FDA-approved therapy as retina, glaucoma, and dry eye pipelines surge—plus AI, devices, and workforce trends reshaping care.

Retina specialists Baruch D. Kuppermann, MD, PhD, and Firas M. Rahhal, MD, discuss the significance of bevacizumab-vikg's approval for wet AMD and its impact on physicians and patients.